Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G 1
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Some tumor cells can be stimulated to differentiate and undergo terminal cell division and loss of tumorigenicity. The in vitro differentiation of murine erythroleukemia (MEL) cells is a dramatic example of tumor-cell reprogramming. We found that reentry of MEL cells into terminal differentiation is accompanied by an early transient decline in the activity of cyclin-dependant kinase (CDK) 2, followed by a decline of CDK6. Later, as cells undergo terminal arrest, CDK2 and CDK4 activities decline. By analyzing stable MEL-cell transfectants containing vectors directing inducible expression of specific CDK inhibitors, we show that only inhibitors that block the combination of CDK2 and CDK6 trigger differentiation. Inhibiting CDK2 and CDK4 does not cause differentiation. Importantly, we also show that reprogramming through inhibition of CDKs is restricted to G 1 phase of the cell cycle. The results imply that abrogation of normal cell-cycle controls in tumor cells contributes to their inability to differentiate fully and that restoration of such controls in G 1 can lead to resumption of differentiation and terminal cell division. The results also indicate that CDK4 and CDK6 are functionally distinct and support our hypothesis that the two CDKs regulate cell division at different stages of erythroid maturation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Differentiation induction of haematological malignant cells as well as normal HSC differentiation is mediated by a stochiometric ratio of transcription factors GATA-1 and PU.1 [41], which broadly determine lineage and cooperate with more specific transcription factors such as RAR receptor and CEBP family members [59, 93, 94].”
From PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis (2009) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Correlation of Terminal Cell Cycle Arrest of Skeletal Muscle with Induction of p21 by MyoD
Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., & Lassar, A. B. (1995) · Science · doi:10.1126/science.7863327 · Cited by 1,149
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119
Research works printed but not linked: 9
- D M Livingston Biochim Biophys Acta 1332, R25–R31 (1997).
- 10.1128/mcb.14.3.2066-2076.1994 · doi:10.1128/mcb.14.3.2066-2076.1994 · Paper page
- 10.1128/mcb.14.11.7195-7203.1994 · doi:10.1128/mcb.14.11.7195-7203.1994 · Paper page
- 10.1182/blood.V96.8.2755 · doi:10.1182/blood.v96.8.2755
- J Wang, K Guo, K N Wills, K Walsh Cancer Res 57, 351–354 (1997).
- T Akagi, H Ono, K Shimotohno Oncogene 13, 399–405 (1996).
- M Chilosi, C Doglioni, Z Yan, M Lestani, F Menestrina, C Sorio, A Benedetti, F Vinante, G Pizzolo, G Inghirami Am J Pathol 152, 209–217 (1998).
- M Vairapandi, A G Balliet, A J Fornace, B Hoffman, D A Liebermann Oncogene 12, 2579–2594 (1996).
- H R Lee, T H Chang, M J Tebalt, A M Senderowicz, E Szabo Int J Oncol 15, 161–166 (1999).
Cited by
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
“(Matushansky et al., 2000).”
Ruijtenberg, S., & van den Heuvel, S. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120925 · Cited by 553
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
“Third, in some instances, inhibition of CDKs contributes to cell differentiation [ 15 ].”
BackgroundRoscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Oh, H., Taffet, G. E., Youker, K. A., Entman, M. L., Overbeek, P. A., Michael, L. H., & Schneider, M. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191169098 · Cited by 289
Metadata
- Authors
- Matushansky, I., Radparvar, F., & Skoultchi, A. I.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-12-12
- Volume
- 97
- Issue
- 26
- Pages
- 14317-14322
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18916
- OpenAlex
- W2162429172
- Cited by
- 84
- References
- 48
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 4 · 2017: 2 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 2
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (T32AG000194)
- National Cancer Institute (P30CA013330)
- National Institute of General Medical Sciences (5T32GM07288-25, T32GM007288)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- leukemia cell differentiation, terminal differentiation, cyclin-dependent kinases, CDK2, CDK4, CDK6, murine erythroleukemia cells, G1 phase, cell cycle regulation, cyclin-dependent kinase inhibitors, erythroid maturation, tumor reprogramming
- MeSH terms
- Animals, Cell Cycle, Cell Differentiation, Leukemia, Erythroblastic, Acute, Humans, Proto-Oncogene Proteins, Tumor Cells, Cultured, G1 Phase, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G 1. https://app.cochat.ai/papers/10.1073/pnas.250488697
- The paper
- Matushansky, I., Radparvar, F., & Skoultchi, A. I. (2000). Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G 1. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.250488697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.